在睡眠中使用高剂量皮质类固醇治疗性脑病的探索性分析,该疗法在睡眠中具有尖峰和波激活
Hu Xiaoyue1, Tang Hongwei1, Wang Jianbiao1
1Department of Neurology, Wuxi Children's Hospital, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
高剂量的皮质类固醇对于在睡眠中具有尖峰和波激活 (EE-SWAS) 的性脑病是有效的,但具有显著的复发率. 发作早期发作和额叶排放预测复发,有助于治疗管理.
科学领域:
- 儿科神经学 儿科神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 临床药理学 临床药理学
背景情况:
- 在睡眠中具有尖峰和波激活 (EE-SWAS) 的脑病在儿科管理中提出了重大挑战.
- 高剂量皮质类固醇治疗是一种潜在的治疗方法,但其疗效和复发模式需要进一步调查.
研究的目的:
- 评估EE-SWAS儿童高剂量皮质类固醇治疗的治疗疗效.
- 确定与治疗结果相关的临床指标.
- 开发一个预测模型,用于EE-SWAS在皮质类固醇治疗后的复发.
主要方法:
- 分析了48名患有EE-SWAS且接受高剂量皮质类固醇的儿童队列.
- 根据治疗结果,患者被分为响应群和非响应群.
- 用单变量和多变量逻辑回归分析确定了复发的风险因素,从而形成了一个预测模型.
主要成果:
- 皮质类固醇治疗的整体有效率为68.8%,在六个月内复发率为33.3%.
- 响应组显示,睡眠中的电状态 (ESES) 的发病年龄较大,使用类的比例较高.
- 同时的额叶放电和较早的发作开始年龄是ESES复发的显著预测因素.
结论:
- 高剂量皮质类固醇治疗在治疗EE-SWAS方面表现出相当大的疗效,尽管复发很常见.
- 复发的预测因素,包括发作开始年龄和额叶放电,可以为临床管理策略提供信息.
- 开发的预测模型为预测EE-SWAS复发后治疗提供了有价值的见解.
更多相关视频
09:06Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
Published on: December 22, 2016
06:28Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems
Published on: September 27, 2024
相关概念视频
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Management of Insomnia
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
REM Sleep Behavior Disorder
RBD is significantly associated with...
